Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

The Lancet Oncology

Volumn 17, Issue 7, 2016, Pages 883-895

  Antonia, Scott J ^a   López Martin, José A ^b   Bendell, Johanna ^c   Ott, Patrick A ^d   Taylor, Matthew ^e   Eder, Joseph Paul ^f   Jäger, Dirk ^g   Pietanza, M Catherine ^h   Le, Dung T ⁱ   de Braud, Filippo ^j   Morse, Michael A ^k   Ascierto, Paolo A ^l   Horn, Leora ^m   Amin, Asim ⁿ   Pillai, Rathi N ^o   Evans, Jeffry ^p   Chau, Ian ^q   Bono, Petri ^r   Atmaca, Akin ^s   Sharma, Padmanee ^t   Harbison, Christopher T ^u   Lin, Chen Sheng ^u   Christensen, Olaf ^u   Calvo, Emiliano ^v   more..

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f YALE CANCER CENTER   (United States)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

^j NATIONAL CANCER INSTITUTE   (Italy)

^k DUKE UNIVERSITY MEDICAL CENTER   (United States)

^l NATIONAL CANCER INSTITUTE   (Italy)

^m VANDERBILT INGRAM CANCER CENTER   (United States)

ⁿ CAROLINAS MEDICAL CENTER   (United States)

^o EMORY UNIVERSITY   (United States)

^p UNIVERSITY OF GLASGOW   (United Kingdom)

^q ROYAL MARSDEN HOSPITAL   (United Kingdom)

^r HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^s KRANKENHAUS NORDWEST   (Germany)

^t UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^u BRISTOL MYERS SQUIBB   (United States)

^v START   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; IPILIMUMAB; NIVOLUMAB; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADRENAL INSUFFICIENCY; ADULT; AGED; ANEMIA; ARTICLE; ASEPTIC MENINGITIS; CARDIOMYOPATHY; COLITIS; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENCEPHALITIS; FATIGUE; FEMALE; FOLLOW UP; HEMORRHAGIC GASTRITIS; HUMAN; HYPERGLYCEMIA; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; HYPONATREMIA; HYPOTHYROIDISM; HYPOXIA; ILEUS; KIDNEY FAILURE; LARGE INTESTINE PERFORATION; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYASTHENIA GRAVIS; NAUSEA; NEUTROPHIL COUNT; NONCARDIAC CHEST PAIN; OPEN STUDY; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; PTOSIS; RASH; SIDE EFFECT; SMALL CELL LUNG CANCER; STOMATITIS; THROMBOCYTOPENIA; TOXIC HEPATITIS; TUMOR LYSIS SYNDROME; VOMITING; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; TUMOR RECURRENCE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

EID: 84971620553     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30098-5     Document Type: Article

References (36)

1. 1 National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Small cell lung cancer. Version 1. http://www.nccn.org (accessed Dec 1, 2015).
2. 2 Byers, LA, Rudin, CM, Small cell lung cancer: where do we go from here?. Cancer 121 (2015), 664–672.
3. 3 Hanna, N, Bunn, PA Jr, Langer, C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24 (2006), 2038–2043.
4. 4 Puglisi, M, Dolly, S, Faria, A, Myerson, JS, Popat, S, O'Brien, ME, Treatment options for small cell lung cancer—do we have more choice?. Br J Cancer 102 (2010), 629–638.
5. 5 Zatloukal, P, Cardenal, F, Szczesna, A, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 21 (2010), 1810–1816.
6. 6 Schmittel, A, Sebastian, M, Fischer von Weikersthal, L, et al., for the Arbeitsgemeinschaft Internistische Onkologie Thoracic Oncology Study Group. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol 22 (2011), 1798–1804.
7. 7 Asai, N, Ohkuni, Y, Kaneko, N, Yamaguchi, E, Kubo, A, Relapsed small cell lung cancer: treatment options and latest developments. Ther Adv Med Oncol 6 (2014), 69–82.
8. 8 Von Pawel, J, Jotte, R, Spigel, DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 32 (2014), 4012–4019.
9. 9 Borghaei, H, Paz-Ares, L, Horn, L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
10. 10 Brahmer, J, Reckamp, KL, Baas, P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
11. 11 OPDIVO (nivolumab) [package insert], 2016, Bristol-Myers Squibb Company, Princeton, NJ.
12. 12 Hodi, FS, O'Day, SJ, McDermott, DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
13. 13 Robert, C, Thomas, L, Bondarekno, I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364 (2011), 2517–2526.
14. 14 Curran, MA, Montalvo, W, Yagita, H, Allison, JP, PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107 (2010), 4275–4280.
15. 15 Hammers, HJ, Plimack, ER, Infante, JR, et al. Expanded cohort results from CheckMate 016: a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol, 33(suppl), 2015, 4516 (abstr).
16. 16 Larkin, J, Chiarion-Sileni, V, Gonzalez, R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
17. 17 Rizvi, NA, Gettinger, SN, Goldman, JW, et al. Safety and efficacy of first-line nivolumab (NIVO; anti-programmed death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC). J Thoracic Oncol, 10(9 suppl), 2015, S176 (abstr 786).
18. 18 Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
19. 19 Wolchok, JD, Kluger, H, Callahan, MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369 (2013), 122–133.
20. 20 Postow, MA, Chesney, J, Pavlick, AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372 (2015), 2006–2017.
21. 21 YERVOY (ipilimumab) [package insert], 2015, Bristol-Myers Squibb Company, Princeton, NJ.
22. 22 Agrawal, S, Feng, Y, Roy, A, Kollia, G, Lestini, B, Nivolumab dose selection: challenges, opportunities and lessons learned for cancer immunotherapy. J Immunother Cancer, 3(suppl 2), 2015, P141.
23. 23 Phillips, T, Simmons, P, Inzunza, HD, et al. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl Immunohistochem Mol Morphol 23 (2015), 541–549.
24. 24 Simon, R, Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10 (1989), 1–10.
25. 25 Loochtan, AT, Nickolich, MS, Hobson-Webb, LD, Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 52 (2015), 307–308.
26. 26 Pietanza, MC, Kadota, K, Huberman, K, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res 18 (2012), 1138–1145.
27. 27 Rudin, CM, Pietanza, MC, Spigel, DR, et al. A DLL3-targeted ADC, rovalpituzumab tesirine, demonstrates substantial activity in a phase I study in relapsed and refractory SCLC. J Thoracic Oncol 10:9 suppl (2015), S192–S193.
28. 28 Wang, W, Hodkinson, P, McLaren, F, et al. Histologic assessment of tumor-associated CD45(+) cell numbers is an independent predictor of prognosis in small cell lung cancer. Chest 143 (2013), 146–151.
29. 29 Buchbinder, EI, Desai, A, CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39 (2015), 98–106.
30. 30 Ott, PA, Elez Fernandez, ME, Hiret, S, et al. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028. J Clin Oncol, 33(suppl), 2015, 7502 (abstr).
31. 31 Royal, RE, Levy, C, Turner, K, et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 33 (2010), 828–833.
32. 32 Maur, M, Tomasello, C, Frassoldati, A, Dieci, MV, Barbieri, E, Conte, P, Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol 30 (2012), e76–e78.
33. 33 Boyd, K, Kalladka, D, Overell, J, Waterston, A, Ipilimumab induced encephalitis: a case report. Immunome Res, 11, 2015, 092.
34. 34 Johnson, DB, Saranga-Perry, V, Lavin, PJ, et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol 33 (2015), e122–e124.
35. 35 Liao, B, Shroff, S, Kamiya-Matsuoka, C, Tummala, S, Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16 (2014), 589–593.
36. 36 Shirai, T, Sano, T, Kamijo, F, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 46 (2016), 86–88.